Fetuin-A Phosphorylation Status in Insulin Resistance and Metabolic Syndrome
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss, Endocrine, Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 30 - 65 |
| Updated: | 4/17/2018 |
| Start Date: | October 10, 2007 |
| End Date: | May 31, 2015 |
Alterations in Phosphorylated Fetuin-A, a Novel Regulator of Insulin Action in Insulin Resistance and Metabolic Syndrome: Effects of Lifestyle Modification
Fetuin-A has been identified as a novel physiological regulator of insulin action in vitro,
in intact cells and in vivo in animals. Previous research has shown that circulating levels
of fetuin-A were increased in animal models of insulin resistance and diabetes. Additionally,
several human investigation studies demonstrate a correlation of fetuin-A levels with body
mass index, insulin resistance, and a fatty liver. Recently, the investigators have
elucidated the role of fetuin-A phosphorylation in the regulation of insulin action,
demonstrating that phosphorylation is critical for the inhibitory activity of fetuin-A. The
objectives of this study are twofold: (1) Quantitate phosphorylated fetuin-A levels in
individuals with insulin resistance and metabolic syndrome, and (2) Investigate the effects
of lifestyle modifications (acute or chronic exercise and dietary modifications) on fetuin-A
phosphorylation and insulin sensitivity.
in intact cells and in vivo in animals. Previous research has shown that circulating levels
of fetuin-A were increased in animal models of insulin resistance and diabetes. Additionally,
several human investigation studies demonstrate a correlation of fetuin-A levels with body
mass index, insulin resistance, and a fatty liver. Recently, the investigators have
elucidated the role of fetuin-A phosphorylation in the regulation of insulin action,
demonstrating that phosphorylation is critical for the inhibitory activity of fetuin-A. The
objectives of this study are twofold: (1) Quantitate phosphorylated fetuin-A levels in
individuals with insulin resistance and metabolic syndrome, and (2) Investigate the effects
of lifestyle modifications (acute or chronic exercise and dietary modifications) on fetuin-A
phosphorylation and insulin sensitivity.
There are several objectives of this study: (1) Quantitate phosphorylated fetuin-A levels and
the daily variation in these levels in individuals with insulin resistance and metabolic
syndrome; (2) Investigate the short-term responses of fetuin-A phosphorylation and changes in
insulin resistance that occur with a single session of aerobic exercise; (3) Characterize and
compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance
that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary
modification, and; (4) Investigate the influence of weight loss on the short-term responses
of fetuin-A phosphorylation and changes in insulin resistance that occur with a single
session of aerobic exercise. Our hypothesis is that phosphofetuin-A levels are tightly
correlated with insulin resistance and that lifestyle modifications will improve insulin
sensitivity and decrease phosphorylated fetuin-A levels.
the daily variation in these levels in individuals with insulin resistance and metabolic
syndrome; (2) Investigate the short-term responses of fetuin-A phosphorylation and changes in
insulin resistance that occur with a single session of aerobic exercise; (3) Characterize and
compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance
that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary
modification, and; (4) Investigate the influence of weight loss on the short-term responses
of fetuin-A phosphorylation and changes in insulin resistance that occur with a single
session of aerobic exercise. Our hypothesis is that phosphofetuin-A levels are tightly
correlated with insulin resistance and that lifestyle modifications will improve insulin
sensitivity and decrease phosphorylated fetuin-A levels.
Inclusion Criteria:
- 30 to 65 years of age
- obese (BMI > 30 kg⋅m2 or % fat > 30, and waist girth > 88 cm)
- weight stable over the previous 6 months
Exclusion Criteria:
- smoker
- documented cardiovascular or metabolic disease
- currently taking medication to alter lipid or glucose metabolism
- practicing regular leisure physical activity over the previous 6 months
- engaged in strenuous vocational activity over the previous 6 months
- signs or symptoms of latent heart disease
- conditions that would preclude treadmill walking
We found this trial at
1
site
Click here to add this to my saved trials
